参考文献:
[1] Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):237-52.
[2] 药物相互作用研究技术指导原则(试行),2021年1月。
[3] Hendrikx JJ, Lagas JS, Wagenaar E, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Br J Cancer. 2014 May 27;110(11):2669-76.
[4] Jackson CGCA, Hung T, Segelov E, Barlow P, Prenen H, McLaren B, Hung NA, Clarke K, Chao TY, Dai MS, Yeh HT, Cutler DL, Kramer D, He J, Zhi J, Chan WK, Kwan R, Deva S. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. Br J Clin Pharmacol. 2021 Dec;87(12):4670-4680.
[5] Karbownik A, Sobańska K, Płotek W, Grabowski T, Klupczynska A, Plewa S, Grześkowiak E, Szałek E. The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid. Invest New Drugs. 2020 Jun;38(3):574-583.
[6] Maeda K. Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. Biol Pharm Bull. 2015;38(2):155-68.
[7] LeBel M, Masson E, Guilbert E, Colborn D, Paquet F, Allard S, Vallée F, Narang PK. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol. 1998 Nov;38(11):1042-50.
[8] Shen H, Yang Z, Mintier G, Han YH, Chen C, Balimane P, Jemal M, Zhao W, Zhang R, Kallipatti S, Selvam S, Sukrutharaj S, Krishnamurthy P, Marathe P, Rodrigues AD. Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation. J Pharmacol Exp Ther. 2013 Mar;344(3):673-85.
[9] Ince I, Knibbe CA, Danhof M, et al. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations [J]. Clin Phar‐
macokinet, 2013, 52: 333-345.
[10] Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4 [J]. Curr Drug Metab, 2008, 9: 310-322.
[11] Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):875-94.
[12] BOGAARDS JJ, BERTRAND M, JACKSON P et al.: Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man.
Xenobiotica (2000) 30:1131-1152
[13] ZUBER R, ANZENBACHEROVA E, ANZENBACHER P: Cytochromes P450 and experimental models of drug metabolism. J. Cell Mol. Med. (2002) 6:189-198.
[14] (a) Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos. 2002 Oct;30(10):1059-62. (b) Balani SK, Li P, Nguyen J, Cardoza K, Zeng H, Mu DX, Wu JT, Gan LS, Lee FW. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metab Dispos. 2004 Oct;32(10):1092-5.
[15] Eng H, Niosi M, McDonald TS, Wolford A, Chen Y, Simila ST, Bauman JN, Warmus J, Kalgutkar AS. Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor. Xenobiotica. 2010 Jun;40(6):369-80.
[16] Shimizu M, Fukami T, Nakajima M, Yokoi T. Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab Dispos. 2014 Jul;42(7):1103-9.
[17] Kamal MA, Shakil S, Nawaz MS, Yu QS, Tweedie D, Tan Y, Qu X, Greig NH. Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses. CNS Neurol Disord Drug Targets. 2017;16(7):820-827.
[18] Suzuki E, Nakai D, Yamamura N, Kobayashi N, Okazaki O, Izumi T. Inhibition mechanism of carbapenem antibiotics on acylpeptide hydrolase, a key enzyme in the interaction with valproic acid. Xenobiotica. 2011 Nov;41(11):958-63.
[19] Di L. The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics. Curr Drug Metab. 2019;20(2):91–102.
[20] Mannervik B, Board PG, Hayes JD, Listowsky I, Pearson WR. Nomenclature for mammalian soluble glutathione transferases. Methods Enzymol. 2005;401:1-8.
[21] Doerksen MJ, Seo D, Smith AD, Jones RS, Coughtrie MWH, Collier AC. Comparisons between human and rodent hepatic glutathione S-Transferase activities reveal sex and species differences. Xenobiotica. 2023 Apr;53(4):223-230.
[22] Ploemen, J. H.; van Ommen, B.; Bogaards, J. J.; van Bladeren, P. J., Ethacrynic Acid and
its Glutathione Conjugate as Inhibitors of Glutathione S-transferases. Xenobiotica 1993, 23
(8), 913-923.
[23] Chen C, Wu C, Lu X, Yan Z, Gao J, Zhao H, Li S. Coniferyl Ferulate, a Strong Inhibitor of Glutathione S-Transferase Isolated from Radix Angelicae sinensis, Reverses Multidrug Resistance and Downregulates P-Glycoprotein. Evid Based Complement Alternat Med. 2013;2013:639083.
[24] Yang X, Ong HW, Dickmander RJ, Smith JL, Brown JW, Tao W, Chang E, Moorman NJ, Axtman AD, Willson TM. Optimization of 3-Cyano-7-cyclopropylamino-pyrazolo[1,5-a]pyrimidines toward the Development of an In Vivo Chemical Probe for CSNK2A. ACS Omega. 2023 Oct 10;8(42):39546-39561.